GTR was performed in 28.6% of IDH-mutant astrocytomas vs. 40.2% of IDHwt GBMs, STR in 21.4% vs. 31.8%, and biopsy alone in 35.7% vs. 19.6%. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).